Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Follow usFrontline Forum is a live, 90-minute moderator guided workshop featuring KOLs who discuss real world evidence, data readouts, and more from conferences around a specific disease state or topic.This new program provides real-time feedback from trusted experts.Our KOLs work on the frontline of patient care.